ACOR - アコ―ダ・セラピュ―ティクス (Acorda Therapeutics Inc.) アコ―ダ・セラピュ―ティクス

 ACORのチャート


 ACORの企業情報

symbol ACOR
会社名 Acorda Therapeutics Inc (アコ―ダ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アコーダ・セラピューティクス(Acorda Therapeutics Inc.)はバイオ医薬品会社である。同社は神経障害患者を治療する療法の開発に従事する。同社は多発性硬化症(MS)患者の歩行を改善するための10ミリグラム(mg)のAmpyra(dalfampridine)延長放出錠剤を含む3件の米国食品医薬品局(FDA)承認治療薬を販売する。同社はまたZanaflexカプセルとタブレット、痙縮の管理のための短時間作用型の薬であるアメリカ食品医薬品局(FDA)認可薬及び帯状疱疹後神経痛関連の神経障害性疼痛の管理向けのFDA認可皮膚パッチであるQutenzaを販売する。同社はパーキンソン病、偏頭痛、多発性硬化症(MS)等の各種疾患を治療する神経療法のパイプラインを有する。同社の製品候補はレボドパの自己投与吸入用治療製剤であるCVT-301である。   アコ―ダ・セラピュ―ティクスは、米国のバイオ医薬品販売会社。多発性硬化症や脊髄損傷、および神経系の他の疾患の神経機能を改善する新しい治療法の開発および商業化を行う。また、チザニジン塩酸塩を含む「ザナフレックス」錠を販売する。本社は、ニューヨーク州ア―ズリ―。   Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
本社所在地 420 Saw Mill River Road Ardsley NY 10502 USA
代表者氏名 Ron Cohen ロン・コーエン
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 914-347-4300
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数 484人
url www.acorda.com
nasdaq_url https://www.nasdaq.com/symbol/acor
adr_tso
EBITDA EBITDA(百万ドル) 167.04000
終値(lastsale) 17.65
時価総額(marketcap) 838089299.45
時価総額 時価総額(百万ドル) 776.83520
売上高 売上高(百万ドル) 588.93000
企業価値(EV) 企業価値(EV)(百万ドル) 724.12520
当期純利益 当期純利益(百万ドル) -145.06100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acorda Therapeutics Inc revenues increased less than 1% to $259.5M. Net income totaled $38M vs. loss of $27.1M. Revenues reflect Net product revenues increase of 3% to $253.4M also reflect License revenue decrease from $6.7M to $0K Royalty revenues decrease of 11% to $6.1M. Net income reflects Research and development - decrease of 40% to $54.8M (expense).

 ACORのテクニカル分析


 ACORのニュース

   Acorda Provides 2019 Highlights and 2020 Guidance at J.P. Morgan Healthcare Conference  2020/01/15 12:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided 2019 highlights and 2020 guidance and priorities at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. “The approval and launch of INBRIJA was an important milestone for Acorda; we believe this product will become a standard of care in the treatment of OFF episodes in Parkinson’s Disease,” said Ron Cohen, M.D., Acorda’s President and CEO. “In 2020, we plan to build on our experience from the
   The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger  2020/01/03 12:55:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Therapeutics Inc (NASDAQ: APLT ) Ascendis Pharma A/S (NASDAQ: ASND ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Epizyme Inc (NASDAQ: EPZM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) INNATE PHARMA S/S ADR (NASDAQ: IPHA )( announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia) The Medicines Company (NASDAQ: MDCO ) Mesoblast limited (NASDAQ: MESO )(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease) Mirati Therapeutics Inc (NASDAQ: MRTX ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) Otonomy Inc (NASDAQ: OTIC ) Syneos Health Inc (NASDAQ: SYNH ) Urovant Sciences Ltd (NASDAQ: UROV ) Veru Inc (NASDAQ: VERU ) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 2) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Evelo Biosciences Inc (NASDAQ: EVLO ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Wave Life Sciences Ltd (NASDAQ: WVE ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) Stocks In Focus Acorda Gains After Hedge Fund Hikes Stake Acorda Therapeutics …
   Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024  2019/12/26 12:00:00 Business Wire
Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or the “Company”) today announced it has successfully completed its previously announced private ex
   Acorda (ACOR) Down 13.5% Since Last Earnings Report: Can It Rebound?  2019/12/04 16:30:46 Zacks Investment Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Acorda Therapeutics Elects John Kelley Chair, Board of Directors  2019/11/27 12:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that its Board of Directors has elected John Kelley to serve as non-executive board Chair, effective November 25, 2019. Mr. Kelley has been a board member at Acorda since 2008. “I am delighted that John will be chairing Acorda’s board,” said Ron Cohen, M.D., Acorda's President and CEO. “John has extensive senior leadership and commercial experience in the biopharmaceutical industry, and we expect that he wi
   Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call Transcript  2019-05-02
Acorda Therapeutics (ACOR) Q1 2018 Results Earnings Conference Call May 02, 2019, 08:30 AM ET Company Participants Felicia Vonella - Executive Director, IR Ron Cohen - CEO Lauren Sabella - CCO David Lawrence - CTO, Chief of Business Operations & Principal Accounting Officer…
   Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019  2019-04-18 Business Wire
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results onThursday, May 2 at 8:30 a.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) or (734) 385-2616 (internat…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アコ―ダ・セラピュ―ティクス ACOR Acorda Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)